NewEdge Advisors’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.88M | Buy |
67,588
+2,127
| +3% | +$115K | 0.01% | 1026 |
|
|
2026
Q1 | $4.11M | Sell |
65,461
-27,583
| -30% | -$2.21M | 0.01% | 774 |
|
|
2025
Q4 | $8.87M | Sell |
93,044
-26,085
| -22% | -$2.56M | 0.03% | 468 |
|
|
2025
Q3 | $11.6M | Buy |
119,129
+9,816
| +9% | +$1.02M | 0.05% | 357 |
|
|
2025
Q2 | $11.7M | Buy |
109,313
+13,527
| +14% | +$1.37M | 0.06% | 331 |
|
|
2025
Q1 | $9.66M | Buy |
95,786
+6,891
| +8% | +$694K | 0.06% | 334 |
|
|
2024
Q4 | $7.94M | Buy |
88,895
+5,416
| +6% | +$477K | 0.05% | 373 |
|
|
2024
Q3 | $7M | Buy |
83,479
+2,172
| +3% | +$171K | 0.05% | 371 |
|
|
2024
Q2 | $6.26M | Buy |
81,307
+20,644
| +34% | +$1.51M | 0.05% | 383 |
|
|
2024
Q1 | $4.15M | Buy |
60,663
+19,573
| +48% | +$1.26M | 0.04% | 443 |
|
|
2023
Q4 | $2.42M | Sell |
41,090
-10,057
| -20% | -$537K | 0.02% | 600 |
|
|
2023
Q3 | $2.7M | Buy |
51,147
+18,629
| +57% | +$977K | 0.03% | 497 |
|
|
2023
Q2 | $1.76M | Buy |
32,518
+2,041
| +7% | +$107K | 0.02% | 633 |
|
|
2023
Q1 | $1.54M | Buy |
30,477
+4,837
| +19% | +$228K | 0.02% | 618 |
|
|
2022
Q4 | $785K | Buy |
25,640
+3,478
| +16% | +$151K | 0.02% | 596 |
|
|
2022
Q3 | $858K | Sell |
22,162
-4,010
| -15% | -$161K | 0.01% | 703 |
|
|
2022
Q2 | $976K | Buy |
26,172
+13,153
| +101% | +$535K | 0.02% | 674 |
|
|
2022
Q1 | $577K | Sell |
13,019
-3,763
| -22% | -$163K | 0.01% | 814 |
|
|
2021
Q4 | $713K | Buy |
16,782
+1,190
| +8% | +$50K | 0.01% | 900 |
|
|
2021
Q3 | $677K | Buy |
15,592
+8,481
| +119% | +$375K | 0.02% | 667 |
|
|
2021
Q2 | $304K | Buy |
+7,111
| New | +$299K | 0.01% | 897 |
|
|
2020
Q4 | – | Sell |
-10,974
| Closed | -$419K | – | 990 |
|
|
2020
Q3 | $419K | Buy |
10,974
+548
| +5% | +$21.1K | 0.01% | 625 |
|
|
2020
Q2 | $366K | Buy |
10,426
+1,672
| +19% | +$60.2K | 0.01% | 626 |
|
|
2020
Q1 | $286K | Sell |
8,754
-1,858
| -18% | -$72.6K | 0.01% | 613 |
|
|
2019
Q4 | $479K | Sell |
10,612
-846
| -7% | -$35.4K | 0.02% | 542 |
|
|
2019
Q3 | $464K | Buy |
11,458
+2,101
| +22% | +$89K | 0.02% | 515 |
|
|
2019
Q2 | $402K | Buy |
9,357
+1,364
| +17% | +$52.5K | 0.02% | 452 |
|
|
2019
Q1 | $307K | Sell |
7,993
-98
| -1% | -$3.74K | 0.02% | 514 |
|
|
2018
Q4 | $286 | Buy |
8,091
+172
| +2% | +$6.24K | 0.02% | 496 |
|
|
2018
Q3 | $305K | Buy |
+7,919
| New | +$277K | 0.02% | 487 |
|
|
2017
Q3 | – | Sell |
-2,413
| Closed | -$66.5K | – | 455 |
|
|
2017
Q2 | $66.5K | Buy |
+2,413
| New | +$64K | 0.01% | 485 |
|
|
2017
Q1 | – | Sell |
-25,954
| Closed | -$603K | – | 276 |
|
|
2016
Q4 | $603K | Buy |
+25,954
| New | +$566K | 0.17% | 132 |
|
Other funds holding BSX
NewEdge Advisors's BSX Position: Q2 2026 in Review
NewEdge Advisors increased its Boston Scientific (BSX) stake by 3.2% in Q2 2026, buying an estimated $115K and bringing the position to 67,588 shares worth $2.88M. The position accounts for 0.01% of the portfolio, ranked #1026.
NewEdge Advisors first reported a position in BSX in Q4 2016 and has held it in 32 quarters since. The position peaked at $11.7M in Q2 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- NewEdge Advisors held 67,588 shares of Boston Scientific worth $2.88M as of Q2 2026.
- NewEdge Advisors bought 2,127 Boston Scientific shares in Q2 2026, an estimated $115K.
- Boston Scientific made up 0.01% of NewEdge Advisors's portfolio in Q2 2026, its #1026 holding.
- NewEdge Advisors first reported a position in Boston Scientific in Q4 2016 and has held it in 32 quarters since.
- NewEdge Advisors's Boston Scientific position peaked at $11.7M in Q2 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.